PROM1 and neoplasm: GSI-IX DAPT (N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) pre-treatment was able to reduce the number of CD133-expressing cells and sensitized tumor cells to doxorubicin and paclitaxel (17).